Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
-
-
-
-
-
Mots clés
BRAFV600E
Radiotherapy
Dabrafenib
Diagnosis
Survival
Chemoresistance
Colorectal cancer
Metastatic cSCC
Anti-Tumor pharmacology
Adjuvant
Surgical excision
ACTH
BRAFV600-mutant melanoma
Abscopal effect
Trametinib
Immunohistochemistry
Merkel cell carcinoma
ALK
Treatment
Biomarkers
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Mesenchymal stromal cells
Radiofrequency ablation
Wnt
Bisphosphonates bone lesion case report histiocytosis Langerhans cell histiocytosis review
Crizotinib
Polyomavirus
Cancer bronchique non à petites cellules
Abdominal pain
Histiocytosis
Anti-PD-1
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Biliopancreatic diversion
TNM classification
Resistance
EGFR
Anti-PD-1 antibody
2-chlorodeoxyadenosine
Locally advanced
Prognostic
Staging
Melanoma
Bariatric surgery
Follow-up
Anti-PD1 blockade
Osimertinib
Gastric bypass
ADN tumoral circulant
Prognosis
Invasive cutaneous squamous cell carcinoma
Antibody-drug conjugate
Adjuvant therapy
Acute generalized exanthematous pustulosis
Circulating tumor DNA
Advanced melanoma
Nivolumab
Cancer
ALK rearrangement
Sonic Hedgehog
Adjuvant FOLFOX
Circulating cell-free DNA
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Cemiplimab
BRAF V600E
Assisted reproductive techniques
Beta-catenin
Abscopal effect colorectal cancer intratumoral immunotherapy liver metastases radiofrequency
Children
AZD9291
AML
Colorectal carcinoma
Cutaneous squamous cell carcinoma
Prevention
Lung adenocarcinoma
Targeted therapy
BRAFV600E mutation
Colon cancer
Biomarker
Immunotherapy
Non-small cell lung cancer
Androgen insensitivity
BRAF V600-mutation
Molecular targeted therapies
Systemic therapy
Metastatic
BRAF
Biomarkers Colonic neoplasms Machine learning Prognosis Tumour infiltrating lymphocytes
Anti-CTLA-4
Immune checkpoint inhibitor
Antineoplastic agents
Anti-PD1
Advanced
Adverse events
Plasma
Safety
Allelic imbalance
Langerhans cell histiocytosis
Body mass index
Chemotherapy
Immunomodulation